Atypical hemolytic uremic syndrome and eculizumab therapy in children
Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating...
Main Authors: | Seong Heon Kim, Hye Young Kim, Su Young Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Pediatric Society
2018-02-01
|
Series: | Korean Journal of Pediatrics |
Subjects: | |
Online Access: | http://kjp.or.kr/upload/pdf/kjped-61-37.pdf |
Similar Items
-
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
by: Sara Madureira Gomes, et al.
Published: (2021-04-01) -
Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in China
by: Ze-Jia Sun, et al.
Published: (2016-01-01) -
Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience
by: Sam Kant, et al.
Published: (2020-05-01) -
Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome
by: Antonio F. Saad, et al.
Published: (2016-03-01) -
Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
by: Ken Saida, et al.
Published: (2018-12-01)